These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 10221288)

  • 21. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
    Agid O; Lerer B
    Int J Neuropsychopharmacol; 2003 Mar; 6(1):41-9. PubMed ID: 12899735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to an open trial of a second SSRI in major depression.
    Joffe RT; Levitt AJ; Sokolov ST; Young LT
    J Clin Psychiatry; 1996 Mar; 57(3):114-5. PubMed ID: 8617695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
    Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
    J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
    Chengappa KN; Kambhampati RK; Perkins K; Nigam R; Anderson T; Brar JS; Vemulapalli HK; Atzert R; Key P; Kang JS; Levine J
    J Clin Psychiatry; 2001 Jul; 62(7):503-8. PubMed ID: 11488359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday.
    Rothschild AJ
    Am J Psychiatry; 1995 Oct; 152(10):1514-6. PubMed ID: 7573593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
    Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
    World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
    Landén M; Björling G; Agren H; Fahlén T
    J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
    Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.
    Marangell LB; Johnson CR; Kertz B; Zboyan HA; Martinez JM
    J Clin Psychiatry; 2002 May; 63(5):391-5. PubMed ID: 12019662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.
    Thase ME; Blomgren SL; Birkett MA; Apter JT; Tepner RG
    J Clin Psychiatry; 1997 Jan; 58(1):16-21. PubMed ID: 9055832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
    Kennedy SH; Eisfeld BS; Dickens SE; Bacchiochi JR; Bagby RM
    J Clin Psychiatry; 2000 Apr; 61(4):276-81. PubMed ID: 10830148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation.
    Viner MW; Chen Y; Bakshi I; Kamper P
    J Clin Psychopharmacol; 2003 Feb; 23(1):104-6. PubMed ID: 12544386
    [No Abstract]   [Full Text] [Related]  

  • 34. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients.
    Sharpley AL; Attenburrow ME; Hafizi S; Cowen PJ
    J Clin Psychiatry; 2005 Apr; 66(4):450-4. PubMed ID: 15816787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
    Barbosa L; Berk M; Vorster M
    J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Cui X; Calabrese JR; Gao K;
    J Clin Psychopharmacol; 2011 Oct; 31(5):638-42. PubMed ID: 21869688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 38. Gynecomastia with risperidone-fluoxetine combination.
    Benazzi F
    Pharmacopsychiatry; 1999 Jan; 32(1):41. PubMed ID: 10071182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.